Repeat Prescribing Patterns Drive Demand For Specialist-Led Alternatives As Mamedica Warns Patients Are Progressing Beyond First-Line Treatments
- Over 1.1 billion prescription items are dispensed annually in England
- Around 8.7 million adults in England are prescribed antidepressants each year
- Around 1 in 6 UK adults report using complementary or alternative therapies, including acupuncture, herbal medicine and CBD-based products
Patients across the UK are increasingly moving through repeat prescriptions as part of ongoing treatment, sometimes without achieving sustained relief. More than 1.1 billion prescription items are dispensed annually in England, with long-term use rising across areas such as mental health, pain and sleep, including 8.7 million adults prescribed antidepressants each year. What is increasingly being described as “prescription fatigue” is becoming more visible, with around 1 in 6 UK adults already using complementary or alternative therapies such as acupuncture, herbal medicine and CBD-based products. Mamedica, the UK’s largest medical cannabis clinic supporting more than 12,000 patients nationwide, warns that many are progressing beyond first-line treatments, particularly in chronic conditions where symptoms remain ongoing or only partially managed, shaping a shift towards more personalised, specialist care pathways.
The clinic notes that many patients with chronic conditions continue through multiple stages of treatment as part of their care journey, particularly where symptoms persist over time. While repeat prescribing plays a vital role in managing both acute and long-term conditions, there is increasing recognition of the importance of regularly reviewing and adapting treatment approaches to ensure they remain effective and aligned to patient needs. This is often seen in areas such as chronic pain, anxiety and insomnia, where patients may move through different medications or dosages before being referred for specialist input.
Mamedica highlights a growing shift towards more adaptive, patient-centred treatment pathways, particularly for those with complex or treatment-resistant conditions. Rather than a single linear approach, care is increasingly evolving to incorporate a broader range of clinically appropriate options, supported by specialist oversight and ongoing review.
The clinic notes that this shift is already underway, with more patients seeking consultations that focus on long-term outcomes and personalised care. Within regulated clinical frameworks, this includes exploring alternative therapies where appropriate, alongside existing treatments, supported by monitoring and real-world evidence to assess effectiveness over time.
